studies

metastatic/adv melanoma (mML), pembrolizumab based treatment vs. Standard of Care (SoC), meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96] KEYNOTE-002 (2 mg/kg), 2015 0.86 [0.67; 1.10] KEYNOTE-022, 2019 0.76 [0.41; 1.40] 0.80[0.67; 0.95]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-022, 201930%839moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64] KEYNOTE-002 (2 mg/kg), 2015 0.57 [0.45; 0.73] KEYNOTE-022, 2019 0.66 [0.40; 1.08] 0.55[0.46; 0.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-022, 201930%839moderatenot evaluable DORdetailed resultsKEYNOTE-022, 2019 0.41 [0.20; 0.83] 0.41[0.20; 0.83]KEYNOTE-022, 201910%81NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80] KEYNOTE-002 (2 mg/kg), 2015 6.11 [2.77; 13.47] KEYNOTE-022, 2019 0.68 [0.32; 1.47] 3.23[0.69; 15.19]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-022, 2019392%839moderatenot evaluable AE (any grade)detailed resultsKEYNOTE-022, 2019 2.03 [0.18; 23.06] 2.03[0.18; 23.06]KEYNOTE-022, 201910%120NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-022, 2019 2.44 [1.17; 5.12] 2.44[1.17; 5.12]KEYNOTE-022, 201910%120NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-022, 2019 4.10 [0.18; 92.93] 4.10[0.18; 92.93]KEYNOTE-022, 201910%120NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-022, 2019 2.58 [1.16; 5.75] 2.58[1.16; 5.75]KEYNOTE-022, 201910%120NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26] KEYNOTE-002 (2 mg/kg), 2015 0.56 [0.34; 0.93] KEYNOTE-022, 2019 1.36 [0.29; 6.34] 0.68[0.48; 0.96]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-022, 201930%819moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91] KEYNOTE-002 (2 mg/kg), 2015 0.44 [0.25; 0.76] KEYNOTE-022, 2019 3.60 [1.67; 7.74] 0.92[0.29; 2.85]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-022, 2019391%819moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] KEYNOTE-022, 2019 2.02 [0.07; 61.28] 1.62[0.21; 12.60]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-022, 201930%819moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87] KEYNOTE-002 (2 mg/kg), 2015 0.85 [0.32; 2.25] KEYNOTE-022, 2019 2.67 [1.18; 6.03] 1.62[0.86; 3.05]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-022, 2019336%819moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76] KEYNOTE-002 (2 mg/kg), 2015 1.46 [0.40; 5.25] 2.06[0.87; 4.87]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88] KEYNOTE-002 (2 mg/kg), 2015 0.10 [0.01; 0.81] 0.08[0.01; 0.43]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48] 0.96[0.13; 6.84]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48] 0.96[0.13; 6.84]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13] KEYNOTE-002 (2 mg/kg), 2015 0.48 [0.02; 14.37] 1.66[0.25; 11.00]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81] KEYNOTE-002 (2 mg/kg), 2015 0.16 [0.01; 3.17] 0.68[0.10; 4.48]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015233%699moderatenot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10] KEYNOTE-002 (2 mg/kg), 2015 0.23 [0.05; 1.11] 0.23[0.08; 0.70]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 2.26[0.20; 25.79]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 1.43[0.11; 18.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17] KEYNOTE-002 (2 mg/kg), 2015 0.07 [0.00; 1.17] 0.07[0.01; 0.50]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 1.92[0.17; 21.29]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.17; 21.50] 1.21[0.17; 8.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24] 0.18[0.03; 1.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39] KEYNOTE-002 (2 mg/kg), 2015 0.08 [0.00; 1.40] 0.08[0.01; 0.60]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 1.42[0.11; 18.63]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29] KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.01; 5.32] 0.24[0.03; 2.13]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 3.58[0.38; 34.02]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24] 0.18[0.03; 1.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 1.42[0.11; 18.63]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Vitiligo TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.03; 2.13] 0.24[0.05; 1.12]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-23 22:16 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 283,284,70,235,285,68,127,128,286,69,129 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons